Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
* Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B | * Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B | ||
* Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years | * Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years | ||
== | ==References== | ||
{{ | {{reflist|2}} | ||
[[Category:Endocrine system]] | |||
[[Category:Genetic disorders]] | |||
[[Category:Endocrinology]] | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} |
Revision as of 15:07, 28 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 prevention On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
- Ionized calcium level yearly for MEN 2A
- Parathyroid hormone level yearly for MEN 2A
- Catacholamines, epinephrine and norepinephrine yearly for MEN 2A and MEN 2B
- Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years